Tenderwize
Wróć do wyszukiwania

Open-House Discount Agreement Filgrastim

Techniker Krankenkasse·Hamburg, Germany·Deadline Apr 30, 2028 · 614 days left·Open·Supplies
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2026-08 - Filgrastim

50/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

50 / 100

Złożoność

20 / 100

Czynniki ryzyka

No guaranteed volume or revenue; agreements are non-exclusive and competitors may also join.

Only pharmaceutical entrepreneurs with own marketing authorization can participate; local distributors without such sta...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Supply of Filgrastim medicinal products to German statutory health insurance funds (Techniker Krankenkasse, HEK, hkk) under discount agreements.
  • Contract term: max. 24 months from 01.05.2026 to 30.04.2028.
Pokaż pełne podsumowanie

Open-house procedure for discount agreements on the active substance Filgrastim (biologic) with German statutory health insurers. Contract conclusion possible at any time during the term (max. 24 months from 01.05.2026). No exclusivity, no individual negotiations. Eligibility is strictly limited to pharmaceutical entrepreneurs under § 4 Abs. 18 AMG with a valid marketing authorization for the offered medicinal products. The tender is not a public procurement under EU law but uses the TED form for transparency. No estimated value provided. No procurement documents analyzed.

Ryzyka

No guaranteed volume or revenue; agreements are non-exclusive and competitors may also join.

Only pharmaceutical entrepreneurs with own marketing authorization can participate; local distributors without such sta...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Bidders must be pharmaceutical entrepreneurs (pharmazeutischer Unternehmer) per § 4 Abs. 18 AMG for the offered medicinal products.
  • Valid marketing authorization for the offered medicinal products according to § 21 Abs. 1 AMG (or equivalent right to market).
  • No grounds for revocation or suspension of authorization.

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No award criteria specified; any qualified supplier can join (open-house model).

Zamawiający

Lokalizacja

Hamburg, DEU

Identyfikator

992-80116-93

Działalność

Health

Części (1)

LOT-0001

Open-House Discount Agreement Filgrastim

Conclusion of discount agreements for Filgrastim under § 130a Abs. 8 SGB V. Open-house procedure with uniform conditions, no exclusivity. Performance nationwide (Germany).

SuppliesEU fundedElectronic submission

Lokalizacja

DE600, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Kryteria udzielenia

No award criteria specified; any qualified supplier can join (open-house model).

Termin

Deadline Apr 30, 2028

Szczegóły zamówienia

Data publikacji
18 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
192805-2026

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3